All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-03-19T09:37:09.000Z

What needs to be considered in patients with MPN with COVID-19?

Bookmark this article

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What needs to be considered in patients with MPN with COVID-19?

What needs to be considered in patients with MPN with COVID-19?

To introduce the topic, Barbui discusses a Swedish population-based study that reported that patients with MPN and myelofibrosis were particularly vulnerable to infections. He gives a thorough discussion on the results of an international study evaluating patients with different phenotypes of MPN and COVID-19 conducted by the European LeukemiaNet (ELN). Notably, Barbui believes that patients with MPN with COVID-19 taking ruxolitinib should not discontinue treatment during the acute COVID-19 phase due to its anti-inflammatory properties. Finally, Barbui touches upon the response rate of patients with MPN to COVID-19 vaccines.

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox